Literature DB >> 29199462

Role of genetics in peripheral arterial disease outcomes; significance of limb-salvage quantitative locus-1 genes.

Emmanuel Okeke1, Ayotunde O Dokun1.   

Abstract

Peripheral artery disease is a major health care problem with significant morbidity and mortality. Humans with peripheral artery disease exhibit two major and differential clinical manifestations - intermittent claudication and critical limb ischemia. Individuals with intermittent claudication or critical limb ischemia have overlapping risk factors and objective measures of blood flow. Hence, we hypothesized that variation in genetic make-up may be an important determinant in the severity of peripheral artery disease. Previous studies have identified polymorphism in genes, contributing to extent of atherosclerosis but much less is known about polymorphisms associated with genes that can influence peripheral artery disease severity. This review outlines some of the progress made up-to-date to unravel the molecular mechanisms underlining differential peripheral artery disease severity. By exploring the recovery phenotype of different mouse strains following experimental peripheral artery disease, our group identified the limb salvage-associated quantitative trait locus 1 on mouse chromosome 7 as the first genetic modifier of perfusion recovery and tissue necrosis phenotypes. Furthermore, a number of genes within LSq-1, such as ADAM12, IL-21Rα, and BAG3 were identified as genetic modifiers of peripheral artery disease severity that function through preservation of endothelial and skeletal muscle cells during ischemia. Taken together, these studies suggest manipulation of limb salvage-associated quantitative trait locus 1 genes show great promise as therapeutic targets in the management of peripheral artery disease. Impact statement Peripheral artery disease (PAD) is a major health care problem with significant morbidity and mortality. Individuals with similar atherosclerosis burden do display different severity of disease. This review outlines some of the progress made up-to-date in unraveling the molecular mechanisms underlining differential PAD severity with a focus on the role of the Limb Salvage-associated Quantitative trait locus 1 (LSq-1), a key locus in adaptation to ischemia in PAD.

Entities:  

Keywords:  A disintegrin and metalloproteinase 12; Bcl-2-associated athanogene-3; hind limb ischemia; interleukin-21 receptor; limb salvage quantitative loci 1; peripheral arterial disease

Mesh:

Year:  2017        PMID: 29199462      PMCID: PMC5788144          DOI: 10.1177/1535370217743460

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  65 in total

1.  Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial.

Authors:  Robert J Lederman; Farrell O Mendelsohn; R David Anderson; Jorge F Saucedo; Alan N Tenaglia; James B Hermiller; William B Hillegass; Krishna Rocha-Singh; Thomas E Moon; M J Whitehouse; Brian H Annex
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

Review 2.  Genetics of peripheral artery disease.

Authors:  Nicholas J Leeper; Iftikhar J Kullo; John P Cooke
Journal:  Circulation       Date:  2012-06-26       Impact factor: 29.690

3.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

Authors:  L Norgren; W R Hiatt; J A Dormandy; M R Nehler; K A Harris; F G R Fowkes
Journal:  J Vasc Surg       Date:  2007-01       Impact factor: 4.268

Review 4.  Biomarkers and Genetics in Peripheral Artery Disease.

Authors:  Surovi Hazarika; Brian H Annex
Journal:  Clin Chem       Date:  2016-11-21       Impact factor: 8.327

5.  Natural history of claudication: long-term serial follow-up study of 1244 claudicants.

Authors:  R Aquino; C Johnnides; M Makaroun; J C Whittle; V S Muluk; M E Kelley; S C Muluk
Journal:  J Vasc Surg       Date:  2001-12       Impact factor: 4.268

6.  Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy.

Authors:  Masanori Asakura; Masafumi Kitakaze; Seiji Takashima; Yulin Liao; Fuminobu Ishikura; Tsuyoshi Yoshinaka; Hiroshi Ohmoto; Koichi Node; Kohichiro Yoshino; Hiroshi Ishiguro; Hiroshi Asanuma; Shoji Sanada; Yasushi Matsumura; Hiroshi Takeda; Shintaro Beppu; Michihiko Tada; Masatsugu Hori; Shigeki Higashiyama
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

7.  Genetic background influences therapeutic effectiveness of VEGF.

Authors:  Keiko Fukino; Masataka Sata; Yoshinori Seko; Yasunobu Hirata; Ryozo Nagai
Journal:  Biochem Biophys Res Commun       Date:  2003-10-10       Impact factor: 3.575

Review 8.  Inflammation in atherosclerosis: from pathophysiology to practice.

Authors:  Peter Libby; Paul M Ridker; Göran K Hansson
Journal:  J Am Coll Cardiol       Date:  2009-12-01       Impact factor: 24.094

9.  Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study.

Authors:  Himabindu Vidula; Lu Tian; Kiang Liu; Michael H Criqui; Luigi Ferrucci; William H Pearce; Philip Greenland; David Green; Jin Tan; Daniel B Garside; Jack Guralnik; Paul M Ridker; Nader Rifai; Mary M McDermott
Journal:  Ann Intern Med       Date:  2008-01-15       Impact factor: 25.391

10.  MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice.

Authors:  Angelika Bonauer; Guillaume Carmona; Masayoshi Iwasaki; Marina Mione; Masamichi Koyanagi; Ariane Fischer; Jana Burchfield; Henrik Fox; Carmen Doebele; Kisho Ohtani; Emmanouil Chavakis; Michael Potente; Marc Tjwa; Carmen Urbich; Andreas M Zeiher; Stefanie Dimmeler
Journal:  Science       Date:  2009-05-21       Impact factor: 47.728

View more
  4 in total

1.  ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.

Authors:  HaiFeng Yang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2022-01-24

2.  BAG3 Attenuates Ischemia-Induced Skeletal Muscle Necroptosis in Diabetic Experimental Peripheral Artery Disease.

Authors:  Arul M Mani; Karthik Dhanabalan; Victor Lamin; Thomas Wong; Madhu V Singh; Ayotunde O Dokun
Journal:  Int J Mol Sci       Date:  2022-09-14       Impact factor: 6.208

3.  Different responses of skeletal muscles to femoral artery ligation-induced ischemia identified in BABL/c and C57BL/6 mice.

Authors:  Huiyin Tu; Junliang Qian; Dongze Zhang; Aaron N Barksdale; Michael C Wadman; Iraklis I Pipinos; Yu-Long Li
Journal:  Front Physiol       Date:  2022-09-16       Impact factor: 4.755

Review 4.  Peripheral vascular disease: preclinical models and emerging therapeutic targeting of the vascular endothelial growth factor ligand-receptor system.

Authors:  Vijay Chaitanya Ganta; Brian H Annex
Journal:  Expert Opin Ther Targets       Date:  2021-06-17       Impact factor: 6.797

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.